Rational politherapy with lacosamide: Results of RELACOVA study
Abstract number :
2.264
Submission category :
7. Antiepileptic Drugs
Year :
2011
Submission ID :
14997
Source :
www.aesnet.org
Presentation date :
12/2/2011 12:00:00 AM
Published date :
Oct 4, 2011, 07:57 AM
Authors :
V. Villanueva Haba, E. L pez-Gom riz, J. L pez-Trigo, J. Palau, M. Bonet, N. Torres, T. Villarroya, C. Santaf , E. Noe, R. Mu oz, E. Pajar n, P. Giner
Rationale: Lacosamide (LCM) is a new antiepileptic drug (AED) whose mechanism of action involves the selective enhancement of sodium channel slow inactivation. RELACOVA study is a multicenter prospective collection of patients on LCM.Methods: All the patients with partial epilepsy in which LCM was used according to clinical practice were collected. The information was obtained at baseline, 3 months, 6 months and 12 months. These data included demographics, epilepsy type, number of seizures, prior and concomitant AEDs and dosage of the drugs. Efficacy and adverse events (AE) were analysed according to the concomitant AEDs. Those were classified based on their mechanism of action: Sodium Channel Blokers, SCB (+), (carbamazepine, lamotrigine, oxcarbazepine, phenytoin) and non-sodium channel blokers (-) (all the others AEDs). The analysis of data was done by intention to treatResults: One-hundred sixty one patients with one-year evolution were studied. The number of patients with at least one SCB (+) was 117 and with only SCB (-) was 54. The mean number of prior AEDs was 5.5 in the SCB (+) group and 4.5 in the SCB (-) group. Regarding the efficacy, there was a statistically significant difference in the number of seizure-free patients in the SCB (-) (29.6%) with respect to the SCB (+) group (14,5%) (p 0.004). The difference was also significant when the responders (>50% seizure reduction) were analysed in the SCB (-) (59.2%) with respect to the SCB (+) (37.6%) (p 0.008). Regarding AE, 53.6% of patients reported at least one adverse event in the SCB (+) group and 32% in the SCB (-) group (p 0.011). No statistically significant differences in the dosage decrease of concomitant SCB (+) were observed with respect to the appearance of AE or the withdrawal because of AE. The combinations with levetiracetam and valproic acid were associated with the best resultsConclusions: Efficacy of LCM has been proved as add-on therapy in epilepsy. The efficacy seems to be higher when used with SCB (-) and the number of AE lower combining with this group. The optimisation of therapy can help to increase control of epilepsy patients
Antiepileptic Drugs